Suggested remit: To appraise the clinical and cost effectiveness of Odevixibat (A 4250) within its marketing authorisation for treating progressive familial intrahepatic cholestasis.
 
Status In progress
Process HST
ID number 1570

Provisional Schedule

Committee meeting: 2 10 November 2021
Expected publication 26 January 2022

Project Team

Project lead Joanne Ekeledo

Email enquiries

Evidence Review Group / Assessment Group School of Health and Related Research (ScHARR), University of Sheffield

Consultees

Companies sponsors Albireo (obevixibat)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Children’s Liver Disease Foundation
Professional groups British Association for the Study of the Liver
  Royal College of Paediatrics and Child Health
  Royal College of Physicians

Commentators

Associated public health groups None
Comparator companies None
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups None

Timeline

Key events during the development of the guidance:

Date Update
16 September 2021 - 07 October 2021 Evaluation consultation: 1
05 August 2021 Committee meeting: 1
02 March 2021 Invitation to participate
02 March 2021 In progress. In progress
15 July 2020 - 12 August 2020 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE highly specialised technologies guidance